This company has been marked as potentially delisted and may not be actively trading. Oyster Point Pharma (OYST) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock OYST Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and InnovationApril 1, 2025 | finance.yahoo.comBillion-dollar real estate bet could spark a biotech revivalMarch 21, 2025 | bizjournals.comVibrant Wintertime Flower At Oyster Point: PhotoFebruary 20, 2025 | msn.comNext phase of Kilroy's big Oyster Point project sees interest beyond biotechFebruary 11, 2025 | bizjournals.comTed Danson, Kristen Bell and D’Arcy Carden Reunite at “A Man on the Inside ”Premiere 4 Years After “The Good Place ”(Exclusive)November 12, 2024 | msn.comTransmucosal Drug Delivery Pipeline Report 2024 - Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesNovember 12, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNovember 7, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy RatingNovember 7, 2024 | markets.businessinsider.comEyePoint Pharma Prices Public Offering Of About 12.73 Mln Shares At $11.00/shrOctober 30, 2024 | markets.businessinsider.comScotiabank Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)October 29, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for DuravyuOctober 29, 2024 | marketwatch.comPositive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy RatingOctober 26, 2024 | markets.businessinsider.comPositive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for DuravyuOctober 25, 2024 | markets.businessinsider.comLights Twinkle As Dusk Descends On Oyster Point: Photo Of The DayOctober 22, 2024 | msn.comViatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A BuyOctober 22, 2024 | seekingalpha.comWest Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes SenseOctober 12, 2024 | seekingalpha.comWegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO saysOctober 11, 2024 | msn.com3 new oyster sanctuary sites, one on lower Eastern Shore, help fuel big Maryland comebackOctober 10, 2024 | msn.comIn critical Ohio Senate race, crypto cash looks to tip the scalesSeptember 23, 2024 | msn.comEyePoint Pharmaceuticals: A Buy Rating Backed by DURAVYU’s Potential and Positive Clinical TrialsSeptember 16, 2024 | markets.businessinsider.comItaly oyster farmers dream of pearls from warming MediterraneanSeptember 10, 2024 | reuters.comAs remote working keeps rolling, Oyster raises $59M Series D at $1.2B valuationSeptember 4, 2024 | msn.comNew Trend Of Pharma Selling Directly To Consumers Raises QuestionsSeptember 4, 2024 | forbes.comEyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)August 30, 2024 | seekingalpha.comSerbia looks to reset ties with US, Israel with first Jewish FM Marko Djuric - interviewAugust 17, 2024 | msn.comThe Oyster Hut to open first brick-and-mortar location in Louise, TexasAugust 15, 2024 | chron.comVibrant Colors Shine In Sunlight At Oyster Point: Photos Of The DayAugust 15, 2024 | msn.comViatris Inc. (VTRS) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comDr. Tyler Hill Joins Oyster Point Oral & Facial SurgeryAugust 8, 2024 | finance.yahoo.comBuy Rating Justified by EyePoint Pharmaceuticals’ Strong Financials and Promising DURAVYU TrialsAugust 7, 2024 | markets.businessinsider.comLawmakers passed a bill specifically to stop their oyster farm. But will it actually work?August 5, 2024 | msn.comConsider the Oyster: The New Lifeblood of Coastal MaineAugust 3, 2024 | msn.comFDA issues advisory for Freeport oysters over potential contaminationJuly 26, 2024 | msn.comViatris 2023 Sustainability Report: Our Strategy and Model for Sustainable Access to MedicineJuly 20, 2024 | finanznachrichten.deaTyr Pharma Buy Rating: Novel Treatment’s Market Potential and Financial UpsideMay 29, 2024 | markets.businessinsider.comThe 32 best beach reads for summer 2024May 25, 2024 | nypost.comNVersant Vantage I GP-GP, LLC's Net WorthMay 25, 2024 | benzinga.comVersant Vantage I, L.P.'s Net WorthMay 22, 2024 | benzinga.comCT unveils the first ‘Oyster Trails' map for restaurants, farms and retailMay 16, 2024 | msn.comMaintained Buy Rating on EyePoint Pharmaceuticals Amid Positive Outlook for EYP-1901 in Wet AMDMay 16, 2024 | markets.businessinsider.comStrong Buy Rating for NewAmsterdam Pharma on Obicetrapib’s Promising Efficacy and Market PotentialMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future ProspectsMay 9, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Q1 Earnings SnapshotMay 8, 2024 | sfgate.comDeep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)May 7, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary EndpointMay 6, 2024 | marketwatch.comEyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary EndpointMay 6, 2024 | marketwatch.comRestored Texas oyster reef aims to revitalize Galveston Bay after difficult seasonMay 1, 2024 | msn.comWhy Big Pharma Is Following Novartis' Lead In A $25 Billion MarketApril 26, 2024 | msn.comReal Americans by Rachel Khong – the lottery of lifeApril 26, 2024 | theguardian.comAs biotech vacancies hit 20%, oversupply of space could crunch crossover developersApril 19, 2024 | bizjournals.com Get Oyster Point Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OYST and its competitors with MarketBeat's FREE daily newsletter. Email Address OYST Media Mentions By Week OYST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OYST News Sentiment▼0.000.55▲Average Medical News Sentiment OYST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OYST Articles This Week▼00▲OYST Articles Average Week Get Oyster Point Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OYST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRME News IKT News PLX News ZIVO News IZTC News CVM News CRTX News ALVR News CLDI News NKGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OYST) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oyster Point Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oyster Point Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access